Başaran, G., Twelves, C., , Cortés, J., & Awada, A. (2017). Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treatment Reviews, 63, 144-155. https://doi.org/10.1016/j.ctrv.2017.12.002 (Original work published 2017)

Schneeweiss, A., Park-Simon, T., Albanell, J., Lassen, U., Cortés, J., , … Cervantes, A. (2018). Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. Investigational New Drugs. https://doi.org/10.1007/s10637-018-0562-4 (Original work published 2018)

Traina, T., Miller, K., Yardley, D., Eakle, J., Schwartzberg, L., O’Shaughnessy, J., … Cortés, J. (2018). Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2016713495. https://doi.org/10.1200/JCO.2016.71.3495 (Original work published 2018)

Cortés, J., Podoltsev, N., Kantarjian, H., Borthakur, G., Zeidan, A., Stahl, M., … Uy, G. (2021). Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. International Journal of Hematology, 113(1), 92-99. https://doi.org/10.1007/s12185-020-02994-8